Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0479 • ACR Convergence 2024
Constructing and Using a Novel Nucleotide Transformer for Patients with Rheumatoid Arthritis
Shant Ayanian, Collin Osborne, Marc Blasi, Daniel Darveaux, Eric Klee and Elena Myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Applying the methods of artificial intelligence (AI) to genomic data for clinical outcome prediction in rheumatoid arthritis (RA) is an area of growing research.…
Abstract Number: 0497 • ACR Convergence 2024
Relationship Between the Complement System and Subclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis
Adrián Quevedo-Rodríguez¹, Marta Hernández-Díaz², Dara Rodríguez-González2², Fuensanta Gomez-Bernal³, Juan Carlos Quevedo-Abeledo⁴, Agustín F González-Rivero², Elena González López⁵, gonzalo Ocejo-Viñals⁵, Miguel Angel Gonzalez-Gay⁶ and ivan Ferraz-Amaro⁷, ¹Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²Hospital Universitario de Canarias, SANTA CRUZ DE TENERIFE, Spain, ³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁴Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁵Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, ⁶University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) events and CV mortality. Carotid subclinical atherosclerosis is independently associated with incident…
Abstract Number: 0514 • ACR Convergence 2024
Efficacy, Safety and Mechanism of Butyrate in the Treatment of Rheumatoid Arthritis (RA)
Jing He¹, Naidi Wang², Yuhui Li³, Ruoyi Wang², Xiao Tan², Runzhi Zhufeng², Yipeng Han², Hao Li², Yuebo Jin² and Zhanguo Li⁴, ¹Rheumatology, Beijing, China, ²Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, ³Peking University, BeiJing, China, ⁴People’s Hospital Peking University Health Sciences Centre, Beijing, China
Background/Purpose: This study aims to investigate the safety and efficacy of butyrate capsules in treating patients with rheumatoid arthritis (RA) and elucidate the underlying mechanisms.Methods:…
Abstract Number: 0532 • ACR Convergence 2024
An Immune-molecular Signature Specifically Modulated by JAK Inhibitors Ex Vivo May Serve as a Predictor of Therapy Response In Vivo to These Drugs
Sagrario Corrales¹, Carlos Perez-Sanchez¹, Laura Muñoz-Barrera¹, Rafaela Ortega-Castro², Elena Moreno-Caño³, Jerusalén Calvo⁴, Concepción Aranda-Valera³, María Lourdes Ladehesa-Pineda⁵, Pilar Font¹, Ismael Sánchez Pareja¹, María Carmen Ábalos-Aguilera⁶, Desiree Ruiz-Vilchez⁴, Christian Merlo⁷, Mª Angeles Aguirre-Zamorano⁸, Tomás Cerdó¹, Nuria Barbarroja¹, Marta Alarcon-Riquelme⁹, Alejandro Escudero-Contreras¹ and Chary Lopez-Pedrera⁵, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Hospital Reina Sofía, Cordoba, Andalucia, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Spain, ⁷Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, ⁸IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, ⁹Fundación Progreso y Salud, Andalusian Government, Granada, Spain
Background/Purpose: Despite significant therapeutic advancements in rheumatoid arthritis (RA), a substantial proportion of patients (20-40%) remain unresponsive to current treatments, including targeted synthetic DMARDs. A…
Abstract Number: 0803 • ACR Convergence 2024
Serum Adipokines and Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort
Anna Haggart¹, Joshua Baker², Tate Johnson³, Yangyuna Yang³, Punyasha Roul⁴, Katherine Wysham⁵, grant Cannon⁶, Gary Kunkel⁷, Dana Ascherman⁸, Paul Monach⁹, Gail Kerr¹⁰, Andreas Reimold¹¹, Michael Duryee³, Geoffrey Thiele³, Ted Mikuls³ and Bryant England³, ¹University of Nebraska Medical Center, Omaha, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴UNMC, Omaha, NE, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Dallas VA Medical Center, Dallas, TX
Background/Purpose: Adipokines are metabolic cytokines shown to be dysregulated in RA and prognostic of RA-related complications such as cardiovascular disease. Similarly, aberrations in adipokines have…
Abstract Number: 0899 • ACR Convergence 2024
Proteomic Insights into JAK Inhibitor Therapeutic Response in Rheumatoid Arthritis
Ting-Shuan Wu¹ and Yi-Ming Chen², ¹Chung Shan Medical University, Taichung, Taiwan (Republic of China), ²Taichung Veterans General Hospital, Taiwan, Taichung, Taiwan (Republic of China)
Background/Purpose: Rheumatoid arthritis (RA) is a common and complex inflammatory polyarthritis. Janus kinase inhibitors (JAKi) have shown superior efficacy compared to traditional treatments, but predictors…
Abstract Number: 0949 • ACR Convergence 2024
CCN1 Is a Novel Therapeutic Target for Reducing Structural Damage in Rheumatoid Arthritis: Demonstration from 2 Preclinical Models
Manon Lesturgie-Talarek¹, Jérôme Avouac², Virginie Gonzalez³, Anne Cauvet¹, Francoise Tilotta⁴ and Yannick Allanore⁵, ¹Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ²Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ³Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, Ile-de-France, France, ⁴UFR Odontologie, and Plateforme Imagerie du Vivant, Université Paris Cité, Montrouge, France, ⁵Université Paris Cité, Paris, France
Background/Purpose: We have previously shown that the matricellular protein CCN1, characterized by angiogenic and immunomodulatory properties, is overexpressed in endothelial cells and synovial tissue of…
Abstract Number: 1016 • ACR Convergence 2024
Pharmacoequity of DMARDs Among Adults with Rheumatoid Arthritis in the U.S
Ashkan Ara¹, Matthew Chenoweth², Srikanth Kadiyala², Utibe Essien³ and Christopher Scannell³, ¹Division of Rheumatology, David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Los Angeles, ²Department of Health Policy and Management, Fielding School of Public Health at UCLA, Los Angeles, ³Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles
Background/Purpose: Long-term management of rheumatoid arthritis (RA) relies on disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic (csDMARDs), biologic (bDMARDs), and targeted synthetic (tsDMARDs). About 40%…
Abstract Number: 1077 • ACR Convergence 2024
Pragmatic Quantitative Rheumatologist 0–10 Visual Numeric Scale Estimates of Inflammation, Damage, and Patient Distress Have Face Validity and May Be as Informative as Formal 28 Joint Counts in Rheumatoid Arthritis
Theodore Pincus¹, tengfei Li² and Juan Schmukler¹, ¹Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, washington dc
Background/Purpose: A 28 joint count of swelling (SJC), tenderness/pain on motion (TJC), and deformity/limited motion (DJC), is recommended to assess rheumatoid arthritis (RA) patient status.…
Abstract Number: 1330 • ACR Convergence 2024
Increased Levels of F-calprotectin in Patients with Early Rheumatoid Arthritis at Diagnosis
Jon Einarsson¹, Katarina Friberger Pajalic², Caroline Bengtsson³, Carmen Roseman⁴, Ellen Landgren¹, Elisabeth Mogard⁵, Elisabet Lindqvist⁵, Tor Olofsson⁴, Johan Karlsson Wallman⁶ and Meliha C Kapetanovic⁴, and Lund Arthritis Research Group (LARG), ¹Lund University, Department of Clinical Sciences Lund, section of rheumatology and Skåne University Hospital Lund, Sweden, Lund, Skane Lan, Sweden, ²Lunds University, Department of clinical sciences, section of Rheumatology Malmö and Skåne University Hospital Malmö, Sweden, Malmö, Sweden, ³Skåne University Hospital Lund, Sweden, Lund, Sweden, ⁴Lund University, Department of Clinical Sciences Lund, section of rheumatology and Skåne University Hospital Lund, Sweden, Lund, Sweden, ⁵Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ⁶Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden
Background/Purpose: Alterations in gut microbiota (dysbiosis) may contribute to the development of rheumatoid arthritis (RA). Elevated fecal calprotectin (F-calprotectin), an established biomarker of gut inflammation, has…
Abstract Number: 1346 • ACR Convergence 2024
Early Diagnosis of Rheumatoid Arthritis: Role of Joint Ultrasound Assessment
Cristina Corrales Selaya¹, Carmen Secada Gómez², Sabela Fernandez-Aguado³, Isla Morante-bolado⁴, Montserrat Santos-gomez⁵, Sara Alonso-Castro⁶, Virginia Portilla-González⁷, Ricardo Blanco-Alonso⁸, Javier Rueda Gotor⁴ and alfonso Corrales-Martínez⁹, ¹Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Universitario Montecelo, Pontevedra, Galicia, Spain, ⁴Hospital Sierrallana, Torrelavega, Cantabria, Spain, ⁵Hospital universitario Central de Asturias, Oviedo, Asturias, Spain, ⁶Hospital Universitario Central de Asturias., Oviedo, Asturias, Spain, ⁷Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁹Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Early diagnosis of Rheumatoid Arthritis (RA) is essential to establish treatment to improve long-term disease outcomes. Musculoskeletal ultrasound (US) is able to detect subclinical…
Abstract Number: 1362 • ACR Convergence 2024
Comparative Effectiveness of Upadacitinib versus Other JAK Inhibitors in Patients with Rheumatoid Arthritis in a Global Real-World Setting
Peter C. Taylor¹, Aditi Kadakia², Jack Milligan³, Sander Strengholt², Oliver Howell³, Pankaj Patel², Sophie Barlow³ and Roberto Caporali⁴, ¹University of Oxford, Oxford, United Kingdom, ²AbbVie Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom, ⁴Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy
Background/Purpose: Network meta-analyses of phase 3 clinical trial data involving JAK inhibitor (JAKi)-treated patients with RA and an inadequate response to conventional synthetic DMARDs showed…
Abstract Number: 1378 • ACR Convergence 2024
Tocilizumab Effect on the Three Pathways of the Complement System in Patients with Rheumatoid Arthritis
Marta Hernández-Díaz¹, Iván Ferraz-Amaro², Sergio Santos-Concepción³, Javier Castro³, Vanesa Hernandez⁴, Beatriz Tejera Segura⁵, Cristina Luna⁶, Esmeralda Delgado-Frías² and Federico Diaz-González², ¹Hospital Universitario de Canarias, SANTA CRUZ DE TENERIFE, Spain, ²Hospital Universitario de Canarias, La Laguna, Spain, ³Universidad de La Laguna, La Laguna, Spain, ⁴Rheumatology department. Hospital Universitario de Canarias, La Laguna, Spain, ⁵Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las palmas, Spain, ⁶Hospital Universitario Nuestra Señora de La Candelaria, Santa Cruz, Spain
Background/Purpose: Tocilizumab (TCZ) is used in diseases characterized by markedly elevated inflammatory markers and elevated pro-inflammatory cytokines like rheumatoid arthritis (RA), juvenile idiopathic arthritis and…
Abstract Number: 1395 • ACR Convergence 2024
Effects of Butyrate Supplementation in Modulation of Gut Microbiome and Its Metabolites in New Onset Rheumatoid Arthritis
Rebecca Blank¹, Alba Boix-Amoros², Erin Reilly³, Kevin Bu⁴, Ian Cunningham⁵, Renuka Nayak⁶, Andrew Patterson⁷, Jose Clemente⁴ and Jose Scher⁸, ¹NYU, New York, NY, ²Icahn School of Medicine, New York, NY, ³Penn State, State Park, PA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶University of California, San Francisco (UCSF), San Francisco, CA, ⁷Penn State University, State College, PA, ⁸New York University School of Medicine, New York, NY
Background/Purpose: The gut microbiome and its metabolites are dysregulated in RA and other immune-mediated inflammatory diseases. However, the significance of this observation and its implications…
Abstract Number: 1663 • ACR Convergence 2024
Notch—mediated Fibrogenic Activation Is a Spatial Determinant of RA Treatment Response
Kartik Bhamidipati¹, Ce Gao¹, Ksenia Anufrieva², Shideh Kazerounian³, Roopa Madhu⁴, Miles Tran¹, Vikram Khedgikar¹, Sonia Presti¹, Anna Helena Jonsson⁵, ilya Korsunsky¹ and Kevin Wei⁶, ¹Brigham and Women's Hospital, Boston, MA, ²BWH, Cambridge, MA, ³Brigham & Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵University of Colorado School of Medicine, Aurora, CO, ⁶Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: In RA, poor treatment response has been linked to a fibroid synovial tissue phenotype, characterized by lack of immune cell infiltration and an expansion…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].